A randomized trial found that microneedling improved outcomes in localized alopecia areata, and that the combination arms did better than needling alone. The trial enrolled 75 people and compared microneedling on its own with microneedling plus topical vitamin D3 or bimatoprost; all groups improved from baseline, while the combination groups had higher regrowth scores at the end of treatment the localized-AA randomized trial.
What did the trial find?
All groups improved from baseline, and the combination groups had higher regrowth scores than microneedling alone. The randomized trial compared microneedling alone with microneedling plus topical vitamin D3 or bimatoprost in 75 people with localized alopecia areata, and reported lower SALT scores across all groups alongside the higher regrowth scores in the combination arms the localized-AA randomized trial.
The SALT score is the standard severity measure for this condition, so a lower score describes a smaller affected area rather than a subjective impression. That makes the reported change comparable across the groups in the trial.
Why do the combination arms matter?
Because they show the better-supported plan is needling plus a topical partner rather than needling by itself. The trial was designed as a comparison, and the comparison produced a direction: the combination groups scored higher on regrowth than microneedling alone. That is a comparative finding, and it is the shape of the evidence worth planning around.
The comparison is the finding, and it is the part worth planning around.
Who does this apply to?
It applies to localized alopecia areata. The trial covered that condition only, so a different diagnosis means a different evidence base — and the combination result is the part worth carrying forward.
We present the scalp evidence as combination treatment and route diagnosis and protocol decisions to a qualified clinician, because which condition a person has decides which evidence applies. Hair loss covers the separate pattern-hair-loss evidence.
What should you do next?
Take the diagnosis and the protocol question to a clinician, and treat the evidence as support for a combination plan. Product clarity comes after that step: documented device identity, cartridge interfaces and ordering information are available once the clinical route and the goal are established. Asking about the combination first keeps the equipment decision in its proper place. It also means the equipment you buy matches the plan you were given, rather than the plan being fitted around the equipment.
Contraindications covers who should not have the procedure, and reported reactions covers the early reaction to expect after a session.
Frequently asked questions
Does microneedling alone treat alopecia areata?
No. The trial reports a comparison, and the combination groups had higher regrowth scores than needling alone. The comparison does not establish a standalone approach.
Does this apply to androgenetic alopecia?
No. The trial covered localized alopecia areata. Pattern hair loss has its own evidence base, covered on hair loss.
How do I turn this finding into a plan?
Treat the comparison as the case for a combination plan, then have the protocol set clinically. The trial reports which approach did better; the dosing and schedule are a clinical decision.
What is a SALT score?
It is the standard severity measure for localized alopecia areata, describing the affected area. A lower score means less area is involved.
Plan the combination, not the needle alone
The evidence points to needling as part of a plan rather than on its own. Read hair loss for the pattern-hair-loss evidence, then contraindications so the clinical conversation starts in the right place.